Renaissance Technologies LLC grew its position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 2.8% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 3,769,888 shares of the biotechnology company's stock after buying an additional 102,692 shares during the period. Renaissance Technologies LLC owned approximately 1.59% of ADMA Biologics worth $64,654,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. National Bank of Canada FI purchased a new position in ADMA Biologics in the 3rd quarter worth approximately $35,000. GAMMA Investing LLC increased its holdings in shares of ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 967 shares in the last quarter. Mark Sheptoff Financial Planning LLC purchased a new position in shares of ADMA Biologics in the fourth quarter worth $35,000. Vision Financial Markets LLC bought a new position in shares of ADMA Biologics during the fourth quarter valued at $51,000. Finally, AlphaQuest LLC purchased a new stake in shares of ADMA Biologics during the fourth quarter valued at $84,000. Institutional investors own 75.68% of the company's stock.
ADMA Biologics Stock Performance
ADMA stock traded up $0.79 during trading on Tuesday, reaching $21.70. The stock had a trading volume of 3,735,798 shares, compared to its average volume of 3,576,526. The firm has a market cap of $5.13 billion, a PE ratio of 77.50 and a beta of 0.53. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The stock's 50 day moving average is $17.86 and its two-hundred day moving average is $18.16. ADMA Biologics, Inc. has a 52 week low of $5.91 and a 52 week high of $23.64.
Wall Street Analysts Forecast Growth
Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price target on shares of ADMA Biologics in a report on Tuesday, March 4th.
Get Our Latest Stock Report on ADMA Biologics
About ADMA Biologics
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Further Reading
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
